Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
06. März 2023 16:05 ET
|
Cyclacel
- On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation - - Expect to...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
27. Februar 2023 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
30. Januar 2023 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
05. Januar 2023 09:15 ET
|
Cyclacel
– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting...
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
15. Dezember 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
09. November 2022 16:05 ET
|
Cyclacel
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and...
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
03. November 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
26. Oktober 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Hosting Research & Development Day
24. Oktober 2022 09:15 ET
|
Cyclacel
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- ...
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
13. Oktober 2022 09:15 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...